WebDoctor Encyclopedia

Soft-tissue sarcomas

Pleomorphic rhabdomyosarcoma

Pleomorphic rhabdomyosarcoma is a rare, fast-growing soft tissue sarcoma of older adults, usually in the thigh or other deep tissues. It is treated like other high-grade adult sarcomas with surgery and radiotherapy, and spread to the lungs is a major risk.

Medically reviewed Last reviewed October 20, 2026

What is pleomorphic rhabdomyosarcoma?

Pleomorphic rhabdomyosarcoma (PRMS) is a rare, aggressive soft tissue sarcoma that develops in adults. It belongs to the rhabdomyosarcoma family, a group of cancers whose cells show features of skeletal muscle, the muscle we use to move. The word pleomorphic means “many shapes”: under the microscope, the tumour contains large, bizarre cells of varying size and shape.

Most rhabdomyosarcomas are childhood cancers, especially the embryonal and alveolar types. Pleomorphic rhabdomyosarcoma is different. It is the main form of rhabdomyosarcoma in adults, usually affecting people in middle and older age, and it behaves more like other high-grade adult sarcomas than like the childhood types (Hollowood and Fletcher, 1994).

PRMS usually appears as a deep, growing lump, most often in the thigh or leg, but it can arise in the trunk, abdomen and other sites. It tends to spread, especially to the lungs, and often returns after treatment.

Treatment is based on surgery with wide margins, usually combined with radiotherapy. Chemotherapy is used for advanced disease, but responses are often limited. Newer research has found that some of these tumours occur in people with Lynch syndrome and may respond to immunotherapy (Poumeaud et al., 2025).

1. Key facts at a glance

Feature Details
Type of cancer High-grade soft tissue sarcoma with skeletal muscle features
Who is affected Adults; median age 54 in one series and 71.5 in another
Sex More common in men
Usual site Deep soft tissue of the lower limb; also trunk, abdomen and other sites
Main symptom A growing, sometimes painful lump
Spread Common, especially to the lungs
Main treatment Wide surgical removal and radiotherapy
Chemotherapy Used in advanced disease; responses often short
Outlook Poor overall; better when the tumour is small and fully removed

2. Types

Rhabdomyosarcoma subtypes

Subtype Usual age Behaviour Typical treatment
Embryonal Children Often responsive to chemotherapy Paediatric chemotherapy, surgery, radiotherapy
Alveolar Children and young adults Aggressive; FOXO1 fusions Paediatric protocols
Spindle cell/sclerosing Children and adults Variable Depends on genetics
Pleomorphic Older adults Aggressive; poor response to chemotherapy Adult sarcoma approach

Variants of pleomorphic rhabdomyosarcoma

A study of 38 adult cases described three variants under the microscope (Furlong, Mentzel and Fanburg-Smith, 2001).

Variant Description Cases
Classic Sheets of large, atypical pleomorphic cells 8
Round cell Clusters of large cells among smaller round cells 13
Spindle cell Scattered large cells among atypical spindle-shaped cells 17

All three behave as high-grade sarcomas.

How it differs from undifferentiated pleomorphic sarcoma

Feature Pleomorphic rhabdomyosarcoma Undifferentiated pleomorphic sarcoma
Muscle markers At least one skeletal muscle-specific marker positive No specific line of differentiation
Outlook Generally poorer Variable
Treatment Similar adult sarcoma principles Similar adult sarcoma principles

Why this tumour was once controversial

For several decades, pathologists debated whether pleomorphic rhabdomyosarcoma truly existed as a separate disease. In the past, many pleomorphic sarcomas were labelled as rhabdomyosarcoma; later, the diagnosis became unfashionable. Modern stains and electron microscopy showed that a genuine group of adult tumours has clear skeletal muscle features and a distinct, aggressive course (Hollowood and Fletcher, 1994). Today, the diagnosis is made only when muscle-specific markers confirm it.

3. Causes and risk factors

Factor Notes
Age Mainly middle-aged and older adults
Male sex In the Furlong series, 28 of 38 patients were men
Lynch syndrome Inherited mismatch repair defect; pleomorphic sarcomas, including PRMS, are over-represented in these patients
Previous radiotherapy A recognised risk factor for sarcomas in general
Lifestyle No known link

Lynch syndrome is an inherited condition that raises the risk of bowel, womb and other cancers. A French national study of 81 people with Lynch syndrome who developed sarcomas found that most of the soft tissue sarcomas had a pleomorphic component, and about a fifth of these were pleomorphic rhabdomyosarcomas. For 40% of patients, the sarcoma was their first cancer (Poumeaud et al., 2025).

The authors recommended testing these tumours for mismatch repair deficiency. This can reveal Lynch syndrome and point to a treatment option.

4. How does it look

On scans

Test Typical findings
MRI Large, deep mass within muscle, often with areas of bleeding or dead tissue
CT of the chest Looks for lung spread
PET-CT Shows spread elsewhere
Ultrasound First test for many lumps; not enough on its own

In the Furlong series, tumours measured from 1.5 to 15 cm, with a median of about 7 cm.

Under the microscope

Feature Description
Cells Large, bizarre, many-shaped cells with abundant pink cytoplasm (rhabdomyoblasts)
Background Round or spindle-shaped tumour cells
Muscle markers Desmin, myogenin (MYF4), MyoD1 and myoglobin
Grade High grade
Mismatch repair proteins Tested to look for Lynch syndrome

Diagnosis requires the typical cells together with at least one skeletal muscle-specific marker (Furlong, Mentzel and Fanburg-Smith, 2001). Desmin was positive in nearly all cases in that study.

5. Symptoms

Common symptoms

  • A lump or swelling, usually deep in the thigh, leg, arm or trunk
  • A lump that grows over weeks or months
  • Pain or tenderness, though some lumps are painless

Less common symptoms

Symptom Possible cause
Abdominal swelling or pain Tumour in the abdomen or retroperitoneum
Scrotal lump Tumour of the spermatic cord
Cough or breathlessness Lung spread
Weight loss and tiredness Advanced disease
Leg swelling Pressure on veins or lymph channels

When to seek medical advice

See a doctor about any lump that is larger than 5 cm, deep under the muscle covering, growing or painful. Ask for referral to a sarcoma service for scans and biopsy.

6. Diagnosis

Test Purpose
MRI of the lump Size, depth and relation to nerves and vessels
Core needle biopsy Planned with the sarcoma team, along the future surgical route
Immunostains Confirm skeletal muscle differentiation
Mismatch repair testing Identifies tumours that may respond to immunotherapy and suggests Lynch syndrome
CT of the chest Staging for lung spread
PET-CT Selected cases
Genetic counselling If Lynch syndrome is suspected

Staging

Staging uses the TNM system for soft tissue sarcoma, taking into account size, depth, grade, nodal spread and distant spread. PRMS is always high grade.

7. Treatment

There is no standard treatment specific to PRMS. Most specialists treat it like other high-grade adult soft tissue sarcomas (Noujaim et al., 2015). Treatment should be given in a specialist sarcoma centre.

Localised disease

Treatment Details
Wide surgical excision Removes the tumour with a margin of healthy tissue; the cornerstone of treatment
Radiotherapy Before or after surgery to reduce the risk of local recurrence
Chemotherapy Sometimes considered for large, high-risk tumours in fit patients
Limb-sparing surgery Usually possible; amputation is rarely needed

What a treatment plan may look like

Step What happens Typical timing
Diagnosis and staging MRI, biopsy, chest CT, pathology review 2-4 weeks
Radiotherapy before surgery Daily weekday sessions About 5 weeks
Rest period Allows swelling to settle 4-6 weeks
Surgery Wide removal of the tumour Hospital stay of several days
Rehabilitation Physiotherapy and wound care Weeks to months

Some centres give radiotherapy after surgery instead; both approaches are used.

Advanced or metastatic disease

Treatment Notes
Doxorubicin, alone or with ifosfamide Common first-line choices
Paediatric-style regimens Used occasionally; benefit uncertain
Immune checkpoint inhibitors Considered for mismatch repair-deficient tumours
Surgery or radiotherapy for lung spread In selected patients with few metastases
Palliative radiotherapy For pain or other symptoms
Clinical trials Encouraged

In a multicentre study of 45 patients, responses to chemotherapy were poor: one partial response and six cases of stable disease, with a median progression-free survival of just over two months (Noujaim et al., 2015).

By contrast, in the Lynch syndrome study, half of eight patients treated with immunotherapy responded, including three complete radiological responses (Poumeaud et al., 2025).

Side effects

Treatment Possible side effects
Surgery Wound problems, loss of muscle function, swelling, nerve damage
Radiotherapy Skin reactions, wound healing problems, stiffness, swelling
Doxorubicin Tiredness, hair loss, infection risk, heart effects
Ifosfamide Kidney and bladder effects, confusion
Immunotherapy Inflammation of organs such as bowel, lungs, liver or thyroid

Treatment in older or frail patients

Because PRMS often affects older people, treatment is tailored to fitness. Surgery and radiotherapy may still be possible, while intensive chemotherapy may be avoided. Single-agent drugs, symptom control and good supportive care are important options.

8. Outlook (prognosis)

Study Findings
Furlong et al. (2001), 30 patients with follow-up 70% died of disease, at a mean of 20 months; 27% had no evidence of disease
Noujaim et al. (2015), 45 patients Median survival 12.8 months for localised and 7.1 months for metastatic disease; relapse in 54%

Factors affecting outlook

Factor Effect
Small tumour, completely removed Better chance of long-term control
Spread at diagnosis Poorer outlook
Older age and frailty Limit treatment options
Mismatch repair deficiency May open the option of immunotherapy

These figures are sobering, but they are averages from small studies. Some people, particularly those with small tumours that are fully removed, remain free of disease for many years.

9. Follow-up

Time Typical checks
Years 1-2 Clinic visit, MRI of the original site and chest CT every 3 months
Years 3-5 Every 4-6 months
After 5 years Yearly review
Lynch syndrome Additional screening for bowel, womb and other cancers

10. Living with pleomorphic rhabdomyosarcoma

  • Ask to be treated in a specialist sarcoma centre
  • Work with physiotherapists to regain strength and movement after surgery
  • Report new lumps, cough or breathlessness promptly
  • Ask whether your tumour was tested for mismatch repair deficiency
  • Tell relatives if you are found to have Lynch syndrome, so they can be offered testing
  • Discuss your goals and priorities with your team, particularly if the disease is advanced
  • Seek support from sarcoma charities and palliative care teams when needed

Support and palliative care

Palliative care teams specialise in controlling symptoms such as pain, breathlessness and tiredness, and in supporting families. They can be involved at any stage, not only at the end of life, and work alongside cancer treatment. Many people find that early contact with these teams improves their quality of life.

11. Frequently asked questions

Question Answer
Is it the same as childhood rhabdomyosarcoma? No; it is a distinct adult tumour that behaves and responds differently
Will I lose my limb? Usually not; limb-sparing surgery is possible in most cases
Why is chemotherapy less helpful? This tumour often responds poorly to standard sarcoma drugs
Can immunotherapy help? It may, especially if the tumour is mismatch repair-deficient
Is it inherited? Usually not, but some cases occur in people with Lynch syndrome
Can it come back? Yes; relapse is common, so regular scans are important
How long will treatment take? Usually several months from diagnosis to the end of surgery and radiotherapy
Will I be able to walk normally? Most people regain good function, though some have lasting weakness
Can I get a second opinion? Yes; specialist sarcoma pathology review is recommended

12. Questions to ask your care team

  • Has the diagnosis been confirmed by a sarcoma pathologist?
  • Has my tumour been tested for mismatch repair deficiency?
  • Can the tumour be completely removed?
  • Do I need radiotherapy before or after surgery?
  • Would chemotherapy or immunotherapy help me?
  • Are there clinical trials I could join?
  • What follow-up will I have?
  • Who can I contact for help with pain or other symptoms?
  • Should my family be offered genetic testing?

Resources

  1. Furlong, M.A., Mentzel, T. and Fanburg-Smith, J.C. (2001) ‘Pleomorphic rhabdomyosarcoma in adults: a clinicopathologic study of 38 cases with emphasis on morphologic variants and recent skeletal muscle-specific markers’, Modern Pathology, 14(6), pp. 595-603.
  2. Hollowood, K. and Fletcher, C.D. (1994) ‘Rhabdomyosarcoma in adults’, Seminars in Diagnostic Pathology, 11(1), pp. 47-57.
  3. Noujaim, J. et al. (2015) ‘Adult pleomorphic rhabdomyosarcoma: a multicentre retrospective study’, Anticancer Research, 35(11), pp. 6213-6217.
  4. Poumeaud, F. et al. (2025) ‘Sarcomas developed in patients with Lynch syndrome are enriched in pleomorphic soft-tissue sarcomas and are sensitive to immunotherapy’, European Journal of Cancer, 216, 115196.
  5. National Cancer Institute (2026) Adult Soft Tissue Sarcoma Treatment (PDQ) – Health Professional Version. Available at: https://www.cancer.gov/types/soft-tissue-sarcoma/hp/adult-soft-tissue-treatment-pdq (Accessed: October 2026).

Prepared by the editorial team, October 2026.